Floatz logo

40 assets in Gastroesophageal Adenocarcinoma

Therapeutic assets addressing Gastroesophageal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Oxaliplatin
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP3BB (68)
Pembrolizumab
Gastroesophageal Adenocarcinoma
Diwakar DavarP3BB (67)
Nivolumab
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP2BB (66)
Trastuzumab
Gastroesophageal Adenocarcinoma
UNICANCERP3BB (64)
Capecitabine
Gastroesophageal Adenocarcinoma
Shanghai Zhongshan HospitalP3B (61)
Fluorouracilum
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP3B (61)
Zanidatamab
Gastroesophageal Adenocarcinoma
Tao ZhangP3B (59)
Ipilimumab
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP1/2B (58)
Trifluridine
Gastroesophageal Adenocarcinoma
UNICANCERP2CCC (55)
Cis-Diamminedichloroplatinum Ii
Gastroesophageal Adenocarcinoma
Zhejiang Cancer HospitalP3CCC (54)
Tislelizumab
Gastroesophageal Adenocarcinoma
Jazz PharmaceuticalsP3CCC (54)
Panitumumab
Gastroesophageal Adenocarcinoma
UNICANCERP2CCC (53)
S-1
Gastroesophageal Adenocarcinoma
Tao ZhangP2CCC (53)
Tisleizumab
Gastroesophageal Adenocarcinoma
Tao ZhangP2CCC (53)
Afuresertib
Gastroesophageal Adenocarcinoma
Laekna LimitedP1/2CCC (52)
Docetaxel
Gastroesophageal Adenocarcinoma
Laekna LimitedP1/2CCC (52)
Adebrelimab
Gastroesophageal Adenocarcinoma
Shanghai Zhongshan HospitalP2CCC (51)
Shr-8068
Gastroesophageal Adenocarcinoma
Shanghai Zhongshan HospitalP2CCC (51)
1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO-
Gastroesophageal Adenocarcinoma
Nimbus Saturn, Inc.P1/2CCC (48)
H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Gastroesophageal Adenocarcinoma
Phanes TherapeuticsP1/2CC (47)
68ga-ff58
Gastroesophageal Adenocarcinoma
Novartis PharmaceuticalsP1CC (44)
bhb810
Gastroesophageal Adenocarcinoma
BigHat Biosciences, Inc.P1/2CC (43)
her3-dxd
Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Levofolinic Acid
Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
m28z1xxpd1dnr car
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP1CC (43)
okn4395
Gastroesophageal Adenocarcinoma
EpkinP1CC (43)
Patritumab Deruxtecan
Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Sacituzumab Tirumotecan
Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Tucatinib
Gastroesophageal Adenocarcinoma
PfizerP1CC (43)
177lu-ff58
Gastroesophageal Adenocarcinoma
Novartis PharmaceuticalsP1C (39)
Abbv-400
Gastroesophageal Adenocarcinoma
AbbVieP1C (39)
Disp-10
Gastroesophageal Adenocarcinoma
Dispatch BiotherapeuticsP1C (39)
hh160
Gastroesophageal Adenocarcinoma
Huahui HealthP1C (39)
Optimized Neoantigen Synthetic Long Peptide Vaccine
Gastroesophageal Adenocarcinoma
Washington University School of MedicineP1C (39)
Tipiracil
Gastroesophageal Adenocarcinoma
AbbVieP1C (39)
asp546c
Gastroesophageal Adenocarcinoma
Astellas Pharma Global Development, Inc.P1/2NR ()
Bms-986504
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP1NR ()
qls5316
Gastroesophageal Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.P1NR ()